NO20052988L - Farmakologisk vitreolyse. - Google Patents

Farmakologisk vitreolyse.

Info

Publication number
NO20052988L
NO20052988L NO20052988A NO20052988A NO20052988L NO 20052988 L NO20052988 L NO 20052988L NO 20052988 A NO20052988 A NO 20052988A NO 20052988 A NO20052988 A NO 20052988A NO 20052988 L NO20052988 L NO 20052988L
Authority
NO
Norway
Prior art keywords
eye
vitreous
reduction
plasmin
disorder
Prior art date
Application number
NO20052988A
Other languages
English (en)
Other versions
NO20052988D0 (no
NO333837B1 (no
Inventor
Steve Pakola
Marc De Smet
Original Assignee
Thromb X Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9949140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20052988(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Thromb X Nv filed Critical Thromb X Nv
Publication of NO20052988D0 publication Critical patent/NO20052988D0/no
Publication of NO20052988L publication Critical patent/NO20052988L/no
Publication of NO333837B1 publication Critical patent/NO333837B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24007—Interstitial collagenase (3.4.24.7), i.e. matrix metalloprotease 1 or MMP1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02004—Chondroitin ABC lyase (4.2.2.4), i.e. chondroitinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02005—Chondroitin AC lyase (4.2.2.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02019—Chondroitin B lyase (4.2.2.19)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Insulating Materials (AREA)

Abstract

2005-09-05 Sammendrag Fremgangsmåte for behandling eller forebygging av en forstyrrelse, eller en komplikasjon ved en forstyrrelse, i et øye hos et individ, omfattende at et glasslegeme og/eller en vandig væske bringes i kontakt med et preparat omfattende en trunkert form av plasmin omfattende et katalytisk domene av plasmin (TPCD). TPCD innbefatter, men er ikke begrenset til, miniplasmin, mikroplasmin og derivater og varianter derav. Fremgangsmåtene ifølge oppfinnelsen kan anvendes til redusering av viskositeten av glasslegemet, flytendegjøring av glasslegemet, indusering av Iøsning av bakre glasslegeme, redusering av hemoragisk blod fra øyet, fjerning eller redusering av materialer som er toksiske for øyet, fjerning eller redusering av intraokulære fremmede substanser fra øyet, øking av diffusjon av et preparat administrert til et øye, redusering av ekstraretinal neovaskularisering, og hvilke som helst kombinasjoner derav. Fremgangsmåten kan anvendes i fravær av, eller som et supplement til, vitrektomi.
NO20052988A 2002-12-06 2005-06-17 Anvendelse av en sammensetning som omfatter et trunkert plasminprotein for fremstilling av et medikament for behandling av en lidelse i et øye samt sammensetning og sett. NO333837B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0228409.9A GB0228409D0 (en) 2002-12-06 2002-12-06 Pharmacological vitreolysis
PCT/US2003/038714 WO2004052228A2 (en) 2002-12-06 2003-12-05 Pharmacological vitreolysis

Publications (3)

Publication Number Publication Date
NO20052988D0 NO20052988D0 (no) 2005-06-17
NO20052988L true NO20052988L (no) 2005-09-05
NO333837B1 NO333837B1 (no) 2013-09-30

Family

ID=9949140

Family Applications (4)

Application Number Title Priority Date Filing Date
NO20052988A NO333837B1 (no) 2002-12-06 2005-06-17 Anvendelse av en sammensetning som omfatter et trunkert plasminprotein for fremstilling av et medikament for behandling av en lidelse i et øye samt sammensetning og sett.
NO20121170A NO20121170A1 (no) 2002-12-06 2012-10-12 Farmakologisk vitreolyse
NO20121169A NO343759B1 (no) 2002-12-06 2012-10-12 Første preparat omfattende et trunkert plasminprotein (TPCD) omfattende en katalytisk domene av plasmin og et andre preparat omfattende et ytterligere middel for anvendelse, samt sett.
NO2013016C NO2013016I2 (no) 2002-12-06 2013-11-19 Okriplasmin

Family Applications After (3)

Application Number Title Priority Date Filing Date
NO20121170A NO20121170A1 (no) 2002-12-06 2012-10-12 Farmakologisk vitreolyse
NO20121169A NO343759B1 (no) 2002-12-06 2012-10-12 Første preparat omfattende et trunkert plasminprotein (TPCD) omfattende en katalytisk domene av plasmin og et andre preparat omfattende et ytterligere middel for anvendelse, samt sett.
NO2013016C NO2013016I2 (no) 2002-12-06 2013-11-19 Okriplasmin

Country Status (24)

Country Link
US (11) US7547435B2 (no)
EP (3) EP1581254B1 (no)
JP (4) JP5426063B2 (no)
CN (1) CN100577202C (no)
AT (1) ATE534400T1 (no)
AU (1) AU2003300821C1 (no)
BE (1) BE2013C055I2 (no)
BR (2) BRPI0310144A8 (no)
CA (1) CA2508606C (no)
CY (2) CY1112561T1 (no)
DK (1) DK1581254T3 (no)
ES (2) ES2731625T3 (no)
FR (1) FR13C0052I2 (no)
GB (1) GB0228409D0 (no)
HU (1) HUS1300040I1 (no)
IL (3) IL169008A (no)
LU (1) LU92273I2 (no)
MX (1) MXPA05006038A (no)
NO (4) NO333837B1 (no)
NZ (1) NZ541075A (no)
PT (2) PT2327416T (no)
SI (1) SI1581254T1 (no)
WO (1) WO2004052228A2 (no)
ZA (1) ZA200505193B (no)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7152975B2 (en) * 2000-11-10 2006-12-26 Cooper Vision, Inc. Junctionless ophthalmic lenses and methods for making same
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
PL2246417T3 (pl) 2004-04-22 2015-06-30 Grifols Therapeutics Inc Rekombinacyjnie zmodyfikowana plazmina
JP4796787B2 (ja) 2005-04-28 2011-10-19 富士フイルム株式会社 ラビリンチュラ類への遺伝子導入法
US20060257391A1 (en) * 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
US20080248021A1 (en) * 2005-06-30 2008-10-09 Ista Pharmaceuticals, Inc. Use of Hyaluronidase in Combination with Plasmin for the Induction of Posterior Vitreous Detachment
US8231869B2 (en) * 2005-10-20 2012-07-31 Grifols Therapeutics Inc. Recombinant plasmin for opthalmic indications
US20070134231A1 (en) * 2005-12-13 2007-06-14 Jani Dharmendra M Method for prolonging activity of autodegradable enzymes and compositions thereof
US20070134230A1 (en) * 2005-12-13 2007-06-14 Jani Dharmendra M Method for prolonging activity of autodegradable enzymes
US20070196350A1 (en) * 2006-02-22 2007-08-23 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
US20070212358A1 (en) * 2006-03-10 2007-09-13 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
AU2007247426B2 (en) * 2006-05-04 2012-03-08 Fondation Ophthalmologique Adolf De Rothschild Combination comprising a VEGF inhibitor and a serine protease for treating neovascular diseases
US8101394B2 (en) 2007-11-29 2012-01-24 Grifols Therapeutics Inc. Recombinantly modified plasmin
EP2249863A4 (en) * 2008-01-22 2011-12-28 Omnio Healer Ab METHOD OF ENHANCING WOUND HEALING
JP2011526585A (ja) * 2008-03-31 2011-10-13 スカルセル テラピュティク 皮膚の老化の美容的処置法
UA103771C2 (ru) 2008-06-04 2013-11-25 Грифолз Терапьютикс Инк. Стрептокиназа, активирующая плазмин, способ и набор для получения плазмина
JP5789521B2 (ja) 2009-03-03 2015-10-07 グリフオルス・セラピユーテイクス・インコーポレーテツドＧｒｉｆｏｌｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． プラスミノーゲンを製造するための組成物、方法およびキット；ならびにそれから製造されるプラスミン
US8858924B2 (en) * 2009-03-26 2014-10-14 Warsaw Orthopedic, Inc. Compositions and methods for treatment of hemorrhage
NZ597452A (en) * 2009-07-10 2013-10-25 Thrombogenics Nv Variants of plasminogen and plasmin
WO2011023805A1 (en) 2009-08-28 2011-03-03 Thrombogenics N.V. Use of plasmin for the treatment of filtration failure after trabeculectomy
US20110135626A1 (en) * 2009-12-08 2011-06-09 Alcon Research, Ltd. Localized Chemical Lysis of Ocular Tissue
RU2435553C1 (ru) * 2010-03-10 2011-12-10 Арсений Александрович Кожухов Способ лечения центральных субретинальных кровоизлияний
CA2823491A1 (en) 2011-01-05 2012-07-12 Thrombogenics Nv Plasminogen and plasmin variants
US20120329873A1 (en) * 2011-06-17 2012-12-27 Li yong-xin D-serine for the treatment of visual system disorders
CA2844644A1 (en) 2011-08-12 2013-02-21 Thrombogenics N.V. Plasminogen and plasmin variants
RU2484795C2 (ru) * 2011-08-18 2013-06-20 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ индукции задней отслойки стекловидного тела с помощью миниплазмина
EP2785739B1 (en) 2011-12-01 2017-03-15 ThromboGenics N.V. Improving trabeculectomy outcome
CN103205410B (zh) * 2012-01-13 2018-03-06 蔺莹莹 重组微纤维蛋白溶酶及其制备方法和应用
AU2013254690B2 (en) 2012-04-24 2017-12-07 Thrombogenics N.V. Anti-PDGF-C antibodies
AU2014243925B2 (en) * 2013-03-14 2018-12-06 Wayne State University Method of enhancing delivery of therapeutic compounds to the eye
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
WO2016054079A1 (en) 2014-09-29 2016-04-07 Zyomed Corp. Systems and methods for blood glucose and other analyte detection and measurement using collision computing
FR3034992A1 (fr) 2015-04-15 2016-10-21 Arcadophta Milieu plasmatique ex vivo autologue riche en plasmine et procede d'obtention
EP3395354B1 (en) * 2015-12-18 2024-05-22 Talengen International Limited Plasminogen for use in treating diabetic nephropathy
JP2019500426A (ja) * 2015-12-18 2019-01-10 タレンゲン インターナショナル リミティッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 糖尿病網膜症を予防または治療するための方法
TWI653981B (zh) 2015-12-18 2019-03-21 深圳瑞健生命科學硏究院有限公司 Use of plasminogen for the preparation of a medicament for preventing or treating a condition associated with diabetic nerve injury
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
RU2619991C1 (ru) * 2016-02-18 2017-05-22 Павел Владимирович Лыскин Способ лечения витреомакулярного тракционного синдрома
EP3426685A1 (en) 2016-03-10 2019-01-16 Oxurion NV Posterior ocular fibrosis inhibition by antagonizing placental growth factor
US9554738B1 (en) 2016-03-30 2017-01-31 Zyomed Corp. Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing
WO2018107701A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种新的降血糖和提高糖耐量的药物
US11504407B2 (en) 2017-03-28 2022-11-22 Morinaga Milk Industry Co., Ltd. Bifidobacterium genus bacterium
RU2674926C1 (ru) * 2018-02-01 2018-12-13 Федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации (ФГАУ "НМИЦ "МНТК "Микрохирургия глаза" им. акад. С.Н. Способ оценки эффективности витреолизиса помутнений стекловидного тела
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
CN110361242B (zh) * 2019-08-14 2022-01-18 武汉赛维尔生物科技有限公司 一种用于眼球组织的固定液以及眼球组织制片的预处理方法
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN116716251A (zh) * 2023-06-20 2023-09-08 中国医学科学院北京协和医院 一种玻璃体样本的单细胞处理方法及其应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US658972A (en) * 1900-04-09 1900-10-02 Interchangeable Brake Beam Company Brake-beam.
US2624691A (en) * 1946-04-22 1953-01-06 Parke Davis & Co Fibrinolysin derived from blood and methods of obtaining the same
DK98833C (da) 1961-04-25 1964-05-25 Novo Terapeutisk Labor As Fremgangsmåde til stabilisering af terapeutisk anvendelige plasminopløsninger.
US3234106A (en) * 1962-12-03 1966-02-08 Cutter Lab Soluble, purified profibrinolysin and fibrinolysin and method of producing same
US3950513A (en) * 1965-12-03 1976-04-13 Novo Terapeutisk Laboratorium A/S Process of stabilizing therapeutically useful plasmin solutions
IT1194135B (it) * 1981-01-05 1988-09-14 Novo Industri As Composizioni di plasmina stabilizzata e metodo per la loro preparazione
GB8504025D0 (en) 1985-02-16 1985-03-20 Biopharm Ltd Hyaluronidase
US4774087A (en) * 1987-08-14 1988-09-27 Northwestern University Micro-size fibrinolytic plasmin
US5288485A (en) * 1989-08-31 1994-02-22 Kao Corporation Vasodilating agent
ZA912770B (en) 1990-04-16 1992-01-29 Bethesda Eye Inst Enzymatic disinsertion of vitreous body
US5288489A (en) * 1991-08-28 1994-02-22 Orion Therapeutic Systems, Inc. Fibrinolysis and fibrinogenolysis treatment
WO1994001128A1 (en) * 1992-07-01 1994-01-20 Beth Israel Hospital Boston Enhancement of thrombolytic therapy with deglycosylated plasminogen
US5304118A (en) * 1992-12-16 1994-04-19 Trese Michael T Method for performing a vitrectomy on an eye
US6610292B2 (en) * 1995-11-22 2003-08-26 Ista Pharmaceuticals, Inc. Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders
US5866120A (en) * 1995-11-22 1999-02-02 Advanced Corneal Systems, Inc. Method for accelerating clearance of hemorrhagic blood from the vitreous humor with hyaluronidase
US5973779A (en) 1996-03-29 1999-10-26 Ansari; Rafat R. Fiber-optic imaging probe
US6207066B1 (en) * 1996-07-23 2001-03-27 Nuvue Technologies, L.L.C. Method for purification of a blood component
US6051698A (en) 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US5722428A (en) * 1996-10-29 1998-03-03 Washington University Method for producing a posterior vitreous detachment
US6596725B2 (en) * 1997-02-10 2003-07-22 Inspire Pharmaceuticals, Inc. Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema
KR100566451B1 (ko) 1997-05-22 2006-03-31 이스타 파마슈티칼스, 인크. 안질환 치료에서 초자체액의 액화를 위한 안과용 제제의 제조에 있어서의 히알루로니다제의 용도
EP1053330B1 (en) 1998-02-04 2005-05-04 Thromb-X N.V. Identification, production and use of staphylokinase derivatives with reduced immunogenicity and/or reduced clearance
US6378526B1 (en) 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
US6462071B1 (en) 2000-03-02 2002-10-08 Vitreo-Retinal Technologies, Inc. Agents for intravitreal administration to treat or prevent disorders of the eye
US6733750B1 (en) * 1999-03-09 2004-05-11 Minu, L.L.C. Process and composition for inducing posterior vitreous detachment
US6585972B2 (en) * 1999-03-09 2003-07-01 Gholam A. Peyman Process for crosslinking of collagen in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
US20040081643A1 (en) * 1999-03-09 2004-04-29 Peyman Gholam A. Process for inhibiting vascular proliferation in the eye
US6899877B2 (en) * 1999-03-09 2005-05-31 Minu, L.L.C. Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
EP1229116A4 (en) 1999-11-10 2003-01-22 Ct For Advanced Science & Tech METHOD FOR PRODUCING A CELL FACTION CONTAINING HEMANGIOBLASTES
US6355243B1 (en) * 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
US6964764B2 (en) * 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
DK1297016T3 (da) * 2000-05-12 2006-07-10 Vlaams Interuniv Inst Biotech Anvendelse af placentavækstfaktorinhibitorer til behandling af patologisk angiogenese, patologisk arteriogenese, inflammation, tumordannelse og/eller vaskulær lækage
US7122181B2 (en) 2000-12-19 2006-10-17 Research Development Foundation Lentiviral vector-mediated gene transfer and uses thereof
PT1343903E (pt) * 2000-12-21 2008-02-18 Thrombogenics Nv ''um vector de expressão de levedura e um método de produção de uma proteína recombinante por expressão numa célula de levedura
US20020139378A1 (en) * 2001-03-28 2002-10-03 Trese Michael T. Method for creating a separation of posterior cortical vitreous from the retina of the eye
FI20011132A0 (fi) 2001-05-30 2001-05-30 Innovationsagentur Markkeri hematopoieettisten kantasolujen tunnistamiseen
US7776026B2 (en) * 2002-02-06 2010-08-17 Nuvue Technologies, Inc. Method for vitreous liquefaction
US6787135B2 (en) * 2002-03-13 2004-09-07 William Beaumont Hospital Modification of vitreal matrix metalloproteinase activity
US20040235115A1 (en) * 2002-11-18 2004-11-25 Reed Guy L. Compositions and methods for treating thrombotic disorders
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
US20060257391A1 (en) * 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
US20070212358A1 (en) * 2006-03-10 2007-09-13 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment

Also Published As

Publication number Publication date
NO20121169A1 (no) 2012-10-12
JP5451533B2 (ja) 2014-03-26
PT1581254E (pt) 2012-02-06
ATE534400T1 (de) 2011-12-15
US7803368B2 (en) 2010-09-28
ES2377965T3 (es) 2012-04-03
US20130302304A1 (en) 2013-11-14
FR13C0052I1 (no) 2013-04-10
US20080095753A1 (en) 2008-04-24
NO343759B1 (no) 2019-06-03
SI1581254T1 (sl) 2012-05-31
EP2327416B1 (en) 2019-05-01
NO2013016I1 (no) 2013-11-19
US20090074739A1 (en) 2009-03-19
BE2013C055I2 (no) 2023-03-07
ES2731625T3 (es) 2019-11-18
LU92273I2 (fr) 2013-10-29
GB0228409D0 (en) 2003-01-08
BR0317033A (pt) 2005-10-25
JP2010222369A (ja) 2010-10-07
US20130195887A1 (en) 2013-08-01
US20130202613A1 (en) 2013-08-08
EP2327416A1 (en) 2011-06-01
US9770494B2 (en) 2017-09-26
IL202851A (en) 2015-04-30
US8834869B2 (en) 2014-09-16
US20110171190A1 (en) 2011-07-14
US8383105B2 (en) 2013-02-26
US20080050356A1 (en) 2008-02-28
AU2003300821C1 (en) 2012-03-22
AU2003300821A1 (en) 2004-06-30
CY2013033I1 (el) 2015-11-04
NO20052988D0 (no) 2005-06-17
IL169008A (en) 2011-08-31
JP5996026B2 (ja) 2016-09-21
US7547435B2 (en) 2009-06-16
EP1581254B1 (en) 2011-11-23
IL213838A0 (en) 2011-07-31
EP1581254A4 (en) 2007-03-28
HUS1300040I1 (hu) 2013-08-15
US20150064161A1 (en) 2015-03-05
CA2508606C (en) 2015-07-28
US20110300123A1 (en) 2011-12-08
NO20121170A1 (no) 2012-10-12
US7867489B2 (en) 2011-01-11
BRPI0310144A8 (pt) 2018-04-24
WO2004052228A2 (en) 2004-06-24
ZA200505193B (en) 2007-08-29
FR13C0052I2 (fr) 2014-11-21
CN1738641A (zh) 2006-02-22
US8460655B2 (en) 2013-06-11
US7914783B2 (en) 2011-03-29
US9186394B2 (en) 2015-11-17
JP5739487B2 (ja) 2015-06-24
LU92273I9 (no) 2019-01-15
PT2327416T (pt) 2019-07-04
MXPA05006038A (es) 2006-03-08
CA2508606A1 (en) 2004-06-24
WO2004052228A3 (en) 2004-10-07
NZ541075A (en) 2008-02-29
NO2013016I2 (no) 2017-06-28
EP2327415A1 (en) 2011-06-01
EP1581254A2 (en) 2005-10-05
DK1581254T3 (da) 2012-02-27
CN100577202C (zh) 2010-01-06
JP2006518708A (ja) 2006-08-17
IL202851A0 (en) 2011-07-31
JP2015131842A (ja) 2015-07-23
NO333837B1 (no) 2013-09-30
AU2003300821B2 (en) 2009-07-09
JP2013241448A (ja) 2013-12-05
EP2327415B1 (en) 2017-10-18
HK1082419A1 (en) 2006-06-09
CY1112561T1 (el) 2015-11-04
CY2013033I2 (el) 2015-11-04
JP5426063B2 (ja) 2014-02-26
US20090081187A1 (en) 2009-03-26
US8747842B2 (en) 2014-06-10
US20050118158A1 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
MXPA05006038A (es) Vitreolisis farmacologica.
Danoff et al. Total knee arthroplasty considerations in rheumatoid arthritis
Nava‐Castañeda et al. Randomized, controlled trial of conjunctival autografting combined with subconjunctival bevacizumab for primary pterygium treatment: 1‐year follow‐up
Mian et al. Corneal ulceration and perforation with ketorolac tromethamine (Acular®) use after PRK
Shufelt et al. Safety of testosterone use in women
ATE429914T1 (de) Verwendung von makroliden zur wiederherstellung der kornealempfindungen
NO20031963D0 (no) Fremgangsmåter og preparater for behandling av sykdommer i öyet
Esquenazi et al. Use of autologous serum in corneal epithelial defects post-lamellar surgery
Daly et al. Acute corneal calcification following chemical injury
Dada et al. Primary posterior capsulorhexis with optic capture and intracameral heparin in paediatric cataract surgery
Betts et al. Ginsenoside‐Rb1 Induces ARPE‐19 Proliferation and Reduces VEGF Release
Gad Elkareem et al. Effect of microplasmin on the clearance of vitreous haemorrhage from an experimental model in rabbits
Lee et al. Impact of N-Acetyl-Cysteine on Ischemic Stumps Following Major Lower Extremity Amputation-A Pilot Randomized Clinical Trial
Srinivasan et al. “Old wine in a new bottle”-post COVID-19 infection, central serous chorioretinopathy and the steroids
Weng et al. Ocriplasmin and its role in the management of vitreoretinal interface disorders
ATE293969T1 (de) Verwendung von hydroxyeicosatetraensäure für intraokuläre chirurgie
Law et al. Shockwave therapy for erectile dysfunction: Is it really effective?
Donatucci Male sexual dysfunction-the new millennium
Hafezi et al. Complications of Corneal Cross-Linking
Novikov et al. The Patient Evaluation and Optimization of Modifiable Risk Factors Before Revision THA
Wang Effect of Glyceraldehyde Cross‐Linking on a Rabbit Bullous Keratopathy Model
Thomas Do decongestants improve or slow progression chronic or recurrent rhinosinusitis?
Kronemyer High rate of dissociation observed during exchange of sustained-release intravitreal implant.
KR20070015913A (ko) 당뇨병성 망막병증 및 황반 변성에서의 드루젠 형성의치료용 약제

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: JETREA; REG. NO/DATE: EU/1/13/818/001 20130322

Spc suppl protection certif: 2013016

Filing date: 20131119

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: OKRIPLASMIN; REG. NO/DATE: EU/1/13/818/001 20130322

Spc suppl protection certif: 2013016

Filing date: 20131119

Extension date: 20280315

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: OXURION NV, BE

SPCS Change of name or address of the owner of a supplementary protection certificate

Owner name: THROMBOGENICS NV, BE

Spc suppl protection certif: 2013016

MM1K Lapsed by not paying the annual fees